Apolipoprotein E and alpha1-antichymotrypsin polymorphism in Alzheimer's disease

Ann Neurol. 1996 Oct;40(4):678-80. doi: 10.1002/ana.410400420.

Abstract

A recent observation has shown that a common polymorphism in the alpha1-antichymotrypsin (ACT) gene modifies the apolipoprotein E (ApoE) epsilon4-associated Alzheimer's disease (AD) risk identifying the combination of the ACT/AA and ApoE epsilon4/epsilon4 genotypes as a potential susceptibility marker for AD. We analyzed the segregation of the ApoE and ACT polymorphism in sporadic and familial AD patients. In none of the sporadic AD patients did we find the combination of the ACT/AA and ApoE epsilon4/epsilon4 genotypes. The frequency of ApoE epsilon4/epsilon4 homozygosity in the AD sample resulted highest for the ACT/ TT genotype (17.6%). Our data fail to confirm any additional association with AD beyond the ApoE epsilon4 allele with any ACT genotype, suggesting that ACT does not represent an additional risk factor for AD.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Alleles
  • Alzheimer Disease / genetics*
  • Apolipoproteins E / genetics*
  • Genotype
  • Homozygote
  • Humans
  • Middle Aged
  • Polymorphism, Genetic*
  • alpha 1-Antichymotrypsin / genetics*

Substances

  • Apolipoproteins E
  • alpha 1-Antichymotrypsin

Grants and funding